COYA COYA THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, COYA THERAPEUTICS INC reported revenue of $244K (up 49.0% from a year earlier), net income of −$6.64M and diluted EPS of −$0.28; over the last four quarters revenue was $8.02M and net income −$21.7M; for the fiscal year ended December 2025 revenue was $7.95M, up 123.6% on the year before.
COYA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $7.95M, gross profit n/a, operating income −$22.6M, net income −$21.2M (margin -267.1%), EPS −$1.27
- Fiscal year ended Dec 2024: revenue $3.55M, gross profit n/a, operating income −$17.2M, net income −$14.9M (margin -418.7%), EPS −$0.98
- Fiscal year ended Dec 2023: revenue $6.00M, gross profit n/a, operating income −$7.90M, net income −$7.99M (margin -133.1%), EPS −$0.79
- Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$9.81M, net income −$12.2M (margin n/a), EPS −$4.73
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$4.87M, net income −$4.89M (margin n/a), EPS −$1.89
COYA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $244K (up 49.0% year over year), net income −$6.64M, EPS −$0.28
- Quarter ended Mar 31, 2026: revenue $251K (down 2.6% year over year), net income −$7.21M, EPS −$0.32
- Quarter ended Dec 31, 2025 (from the annual report): revenue $3.96M (up 202768.8% year over year), net income −$5.71M, EPS −$0.34
- Quarter ended Sep 30, 2025: revenue $3.56M, net income −$2.12M, EPS −$0.13
- Quarter ended Jun 30, 2025: revenue $164K (down 95.2% year over year), net income −$6.09M, EPS −$0.36
- Quarter ended Mar 31, 2025: revenue $258K (up 103.3% year over year), net income −$7.31M, EPS −$0.44
- Quarter ended Dec 31, 2024 (from the annual report): revenue $1.95K (down 100.0% year over year), net income −$2.92M, EPS −$0.18
- Quarter ended Sep 30, 2024: revenue $0, net income −$4.02M, EPS −$0.26
- Quarter ended Jun 30, 2024: revenue $3.43M, net income −$2.89M, EPS −$0.19
- Quarter ended Mar 31, 2024: revenue $127K, net income −$5.05M, EPS −$0.35
- Quarter ended Dec 31, 2023 (from the annual report): revenue $6.00M, net income $1.27M, EPS $0.14
- Quarter ended Sep 30, 2023: revenue $0, net income −$3.42M, EPS −$0.34
- Quarter ended Jun 30, 2023: revenue $0, net income −$3.10M, EPS −$0.31
- Quarter ended Mar 31, 2023: revenue $0, net income −$2.74M, EPS −$0.28
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$3.11M, EPS −$1.20
- Quarter ended Sep 30, 2022: revenue n/a, net income −$4.02M, EPS −$1.55
- Quarter ended Jun 30, 2022: revenue n/a, net income −$3.41M, EPS −$1.32
- Quarter ended Mar 31, 2022: revenue n/a, net income −$1.70M, EPS −$0.66
COYA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$10.7M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$10.3M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$11.2M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$7.24M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$3.90M, share buybacks n/a
COYA balance sheet
- Jun 30, 2026: cash $43.2M, total assets $47.3M, total liabilities $4.03M, shareholders' equity $43.3M
- Mar 31, 2026: cash $50.7M, total assets $53.3M, total liabilities $4.30M, shareholders' equity $49.0M
- Dec 31, 2025: cash $46.8M, total assets $50.0M, total liabilities $6.92M, shareholders' equity $43.0M
- Sep 30, 2025: cash $28.1M, total assets $32.0M, total liabilities $4.76M, shareholders' equity $27.3M
- Jun 30, 2025: cash $29.8M, total assets $33.5M, total liabilities $5.14M, shareholders' equity $28.3M
- Mar 31, 2025: cash $35.5M, total assets $38.4M, total liabilities $5.04M, shareholders' equity $33.4M
- Dec 31, 2024: cash $38.3M, total assets $44.3M, total liabilities $4.77M, shareholders' equity $39.6M
- Sep 30, 2024: cash $31.1M, total assets $35.6M, total liabilities $3.54M, shareholders' equity $32.0M
What is COYA's revenue?
COYA THERAPEUTICS INC reported $8.02M of revenue over its last four quarters, through June 30, 2026.
Is COYA profitable?
No. COYA THERAPEUTICS INC lost $21.7M over the last four quarters.
What is COYA's EPS?
Diluted earnings per share over the last four quarters were −$1.07; −$0.28 in the latest quarter.